---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-029441"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2023-08-18T23:59:59+00:00"
generated_at: "2026-06-11T07:07:02.010967+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ZyVersa CSO retiring Aug 18; annual meeting Oct 31, proposal deadline Aug 30

## Summary
- CSO Nicholas A. LaBella, Jr. notified planned retirement effective August 18, 2023.
- He is expected to remain as a member of the Scientific Advisory Board post-retirement.
- Company will enter a separation agreement for compensation related to his departure.
- 2023 annual meeting of stockholders set for Tuesday, October 31, 2023.
- Deadline for stockholder proposals and director nominations is August 30, 2023.

## SEC filing metadata
- accession: 0001493152-23-029441
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2023-08-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.08
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315223029441/0001493152-23-029441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315223029441/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-029441
- JSON: https://secwatch.observer/filing/0001493152-23-029441.json
- Plain text: https://secwatch.observer/filing/0001493152-23-029441.txt

## Key facts
- Executive change
  Nicholas A. LaBella, Jr. retired as Chief Scientific Officer and Senior Vice President of Research and Development at ZyVersa Therapeutics, Inc..
  - Action: retired
  - Role: Chief Scientific Officer and Senior Vice President of Research and Development
  source text: On August 7, 2023, Nicholas A. LaBella, Jr., Chief Scientific Officer and Senior Vice President of Research and Development at ZyVersa Therapeutics, Inc. (the “Company”) notified the Company of his planned retirement from the Company effective August 18, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223029441/0001493152-23-029441-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.